Showing results (151-160 of 236) with videos related to

Sort By:
Pageof 24
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2005
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individualsGiorgio Antonucci, Enrico Girardi, Alessandro Cozzi-Lepri, et al.
Nature Communications|January 20, 2021
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, ItalyClaudia Alteri, Valeria Cento, Antonio Piralla, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 6, 2024
Kinetics of hepatitis B virus replication in anti-HBc positive/HBsAg-negative people with HIV switching to tenofovir sparing therapyRomina Salpini, Stefano D'Anna, Mohammad Alkhatib, et al.
Plos One|September 1, 2023
Quantitative SARS-CoV-2 subgenomic RNA as a surrogate marker for viral infectivity: Comparison between culture isolation and direct sgRNA quantificationRossana Scutari, Silvia Renica, Valeria Cento, et al.
Zeitschrift Fur Gesundheitswissenschaften = Journal of Public Health|January 10, 2022
Trends in all-cause mortality of hospitalized patients due to SARS-CoV-2 infection from a monocentric cohort in Milan (Lombardy, Italy)Nicola Ughi, Davide Paolo Bernasconi, Francesca Del Gaudio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 17, 2020
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statementLucia Moiola, Valeria Barcella, Simone Benatti, et al.
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
The Journal of Infection|July 12, 2020
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysisRoberto Rossotti, Giovanna Travi, Nicola Ughi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 17, 2020
Vaccinations in patients with multiple sclerosis: A Delphi consensus statementAgostino Riva, Valeria Barcella, Simone V Benatti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus InfectionEli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.
Pageof 24